Cargando…
Mechanism-based modeling of the effect of a novel inhibitor of vascular adhesion protein-1 on albuminuria and renal function markers in patients with diabetic kidney disease
The vascular adhesion protein-1 (VAP-1) inhibitor ASP8232 reduces albuminuria in patients with type 2 diabetes and chronic kidney disease. A mechanism-based model was developed to quantify the effects of ASP8232 on renal markers from a placebo-controlled Phase 2 study in diabetic kidney disease with...
Autores principales: | Hoefman, Sven, Snelder, Nelleke, van Noort, Martijn, Garcia-Hernandez, Alberto, Onkels, Hartmut, Larsson, Tobias E., Bergmann, Kirsten R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979602/ https://www.ncbi.nlm.nih.gov/pubmed/32929612 http://dx.doi.org/10.1007/s10928-020-09716-x |
Ejemplares similares
-
Population pharmacokinetics and pharmacodynamics of a novel vascular adhesion protein-1 inhibitor using a multiple-target mediated drug disposition model
por: Snelder, Nelleke, et al.
Publicado: (2020) -
A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP‐1 dual agonist
por: Bosch, Rolien, et al.
Publicado: (2021) -
Characterisation of the pharmacokinetics of ethinylestradiol and drospirenone in extended-cycle regimens: population pharmacokinetic analysis from a randomised Phase III study
por: Reif, Stefanie, et al.
Publicado: (2013) -
Albuminuria - marker of progressive renal disease
por: Stoian, M, et al.
Publicado: (2012) -
Dose–Exposure–Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD
por: Goulooze, Sebastiaan Camiel, et al.
Publicado: (2022)